Biomarin Depreciation And Amortization vs Ebit Analysis
BMRN Stock | USD 75.52 0.38 0.50% |
Biomarin Pharmaceutical financial indicator trend analysis is way more than just evaluating Biomarin Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biomarin Pharmaceutical is a good investment. Please check the relationship between Biomarin Pharmaceutical Depreciation And Amortization and its Ebit accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
Depreciation And Amortization vs Ebit
Depreciation And Amortization vs Ebit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biomarin Pharmaceutical Depreciation And Amortization account and Ebit. At this time, the significance of the direction appears to have strong relationship.
The correlation between Biomarin Pharmaceutical's Depreciation And Amortization and Ebit is 0.64. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Ebit in the same time period over historical financial statements of Biomarin Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Biomarin Pharmaceutical's Depreciation And Amortization and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Biomarin Pharmaceutical are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Depreciation And Amortization i.e., Biomarin Pharmaceutical's Depreciation And Amortization and Ebit go up and down completely randomly.
Correlation Coefficient | 0.64 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Ebit
Most indicators from Biomarin Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Tax Provision is very stable compared to the past year. As of the 28th of May 2024, Enterprise Value Over EBITDA is likely to grow to 74.10, while Selling General Administrative is likely to drop about 246.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.4B | 1.6B | 1.8B | 1.9B | Total Revenue | 1.8B | 2.1B | 2.4B | 2.5B |
Biomarin Pharmaceutical fundamental ratios Correlations
Click cells to compare fundamentals
Biomarin Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biomarin Pharmaceutical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.7B | 5.8B | 6.0B | 6.4B | 6.8B | 7.2B | |
Short Long Term Debt Total | 848.1M | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | |
Other Current Liab | (13.0M) | 289.2M | 329.4M | 346.6M | 354.2M | 372.0M | |
Total Current Liabilities | 932.5M | 492.5M | 539.8M | 588.9M | 1.2B | 1.2B | |
Total Stockholder Equity | 3.1B | 4.1B | 4.3B | 4.6B | 5.0B | 5.2B | |
Property Plant And Equipment Net | 1.0B | 1.0B | 1.0B | 1.1B | 1.1B | 1.2B | |
Net Debt | 410.7M | 426.0M | 491.8M | 358.5M | 378.7M | 216.1M | |
Retained Earnings | (1.7B) | (861.6M) | (925.7M) | (789.2M) | (621.6M) | (652.6M) | |
Accounts Payable | 570.6M | 191.4M | 193.0M | 231.2M | 315.5M | 331.3M | |
Cash | 437.4M | 649.2M | 587.3M | 724.5M | 755.1M | 792.9M | |
Non Current Assets Total | 2.7B | 3.5B | 3.7B | 3.6B | 3.9B | 4.1B | |
Non Currrent Assets Other | 122.0M | 142.2M | 151.8M | 176.2M | 121.2M | 72.7M | |
Cash And Short Term Investments | 753.8M | 1.1B | 1.0B | 1.3B | 1.1B | 595.1M | |
Net Receivables | 377.4M | 448.4M | 373.4M | 461.3M | 633.7M | 665.4M | |
Common Stock Shares Outstanding | 179.0M | 191.7M | 182.9M | 189.0M | 191.6M | 127.6M | |
Liabilities And Stockholders Equity | 4.7B | 5.8B | 6.0B | 6.4B | 6.8B | 7.2B | |
Non Current Liabilities Total | 635.2M | 1.2B | 1.2B | 1.2B | 713.0M | 586.6M | |
Inventory | 680.3M | 698.5M | 776.7M | 894.1M | 1.1B | 1.2B | |
Other Current Assets | 130.7M | 129.9M | 110.4M | 104.5M | 141.4M | 148.5M | |
Other Stockholder Equity | 4.8B | 5.0B | 5.2B | 5.4B | 5.6B | 5.9B | |
Total Liab | 1.6B | 1.7B | 1.7B | 1.8B | 1.9B | 2.0B | |
Property Plant And Equipment Gross | 1.0B | 1.0B | 1.8B | 1.9B | 1.9B | 2.0B | |
Total Current Assets | 1.9B | 2.3B | 2.3B | 2.8B | 3.0B | 3.1B | |
Accumulated Other Comprehensive Income | 20.2M | (16.1M) | 14.4M | (3.9M) | (38.6M) | (36.7M) | |
Intangible Assets | 456.6M | 417.3M | 388.7M | 338.6M | 294.7M | 244.4M | |
Common Stock Total Equity | 178K | 180K | 182K | 184K | 211.6K | 126.8K | |
Short Term Investments | 316.4M | 416.2M | 426.6M | 567.0M | 318.7M | 276.3M | |
Common Stock | 180K | 182K | 184K | 186K | 189K | 133.2K | |
Other Assets | 612.0M | 1.6B | 1.6B | 1.6B | 1.8B | 1.9B | |
Long Term Debt | 486.2M | 1.1B | 1.1B | 1.1B | 593.1M | 553.3M | |
Property Plant Equipment | 1.0B | 1.0B | 1.0B | 1.1B | 1.3B | 1.3B | |
Other Liab | 98.1M | 174.3M | 113.7M | 73.5M | 84.5M | 81.8M | |
Net Tangible Assets | 2.5B | 3.5B | 3.7B | 4.1B | 4.7B | 4.9B | |
Retained Earnings Total Equity | (1.7B) | (1.7B) | (861.6M) | (925.7M) | (833.1M) | (874.8M) | |
Long Term Debt Total | 830.4M | 486.2M | 1.1B | 1.1B | 1.2B | 730.7M | |
Capital Surpluse | 4.7B | 4.8B | 5.0B | 5.2B | 6.0B | 3.7B | |
Long Term Investments | 412.0M | 285.5M | 507.8M | 333.8M | 611.1M | 353.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.722 | Earnings Share 1.06 | Revenue Per Share 13.12 | Quarterly Revenue Growth 0.088 | Return On Assets 0.0177 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.